rabbit anti-mtap polyclonal antibody  (Cell Signaling Technology Inc)

Journal: iScience

Article Title: The PRMT5-splicing axis is a critical oncogenic vulnerability that regulates detained intron splicing

doi: 10.1016/j.isci.2025.112965

Figure Lengend Snippet: PRMT5 regulates a conserved set of DIs across multiple human cell lines (A) Human cell lines used for AS analysis, including cancer or tissue of origin, driver mutations or construct, and MTAP status. (B) Proportion of each AS event type that show significantly altered levels in the indicated cell line in response to 3-day treatment with 10 nM JNJ-64619178 (PRMT5i) compared to vehicle control (p adj < 0.05). The total number of significant AS events for that cell line is indicated to the right of each bar. (C) Relative expression of individual DIs across all human cell lines after 3-day vehicle or PRMT5i treatment. Each column represents a specific DI that is significantly up- or down-regulated by PRMT5i-treatment in at least one cell line. Coloring represents Z score normalized intron counts, where red indicates higher relative expression and blue indicates lower relative expression. (D) Similarity matrix of the indicated AS event significantly altered by PRMT5i treatment (p adj < 0.05). Each square represents the similarity between the two intersecting cell lines, with coloring indicating percent similarity (dice similarity score) and square size indicating the number of similar events. (E) Bar charts of DI conservation across 7 human cell lines. Bar length represents the number of significant PRMT5i-upregulated DIs (p adj < 0.05, log 2 FC > 0) for each cell line and the color denotes the number of cell lines in which a given DI is conserved across. The total number of significant DIs in each line is indicated to the right of each bar. (F) Enriched GO terms from the KW Biological Process gene set for PRMT5i-upregulated DIs in each cell line (p adj < 0.05, log 2 FC > 0). Terms are displayed if they are significant in at least one cell line (FDR < 0.01). Color represents enrichment score, while size inversely correlates with significance value.

Article Snippet: Rabbit anti-MTAP Polyclonal Antibody , Cell Signaling Technology , Cat#4158; RRID: AB_1904054.

Techniques: Construct, Control, Expressing

Journal: iScience

Article Title: The PRMT5-splicing axis is a critical oncogenic vulnerability that regulates detained intron splicing

doi: 10.1016/j.isci.2025.112965

Figure Lengend Snippet: PRMT5 regulates a conserved set of DIs in multiple mouse cell lines (A) Summary of mouse cell lines used for AS analysis, including cancer type, driver mutations, PRMT5i used, and MTAP status. (B) Proportion of each AS event type that is significantly different in indicated cell line after 3-day PRMT5i treatment compared to vehicle control (p adj < 0.05). Total number of significant AS events is indicated above the bar. (C) Relative expression of individual DIs across all mouse cell lines after 3-day vehicle or PRMT5i treatment. Each column represents a specific DI that is significantly upregulated or downregulated by PRMT5i-treatment in at least one cell line. Colors represent column Z score normalized intron counts, where red indicates higher relative expression and blue indicates lower relative expression. (D) Similarity matrix of the indicated class of AS event that was significantly altered by PRMT5i treatment. Each square represents the similarity between the two intersecting murine cell lines. Square coloring indicates percent similarity (dice similarity score), and square size is proportional to the number of similar events. (E) Bar charts of DI conservation across all mouse cell lines. Each bar represents the number of PRMT5i-upregulated DIs (p adj < 0.05, log 2 FC > 0) in each cell line and the color corresponds to the number of cell lines in which a given DI is conserved across. Total number of significant DIs in each line is indicated to the right of the bar. (F) Enriched GO terms from the KW Biological Process gene set for PRMT5i-upregualted DIs in each cell line (p adj < 0.05, log 2 FC > 0). Terms are displayed if they are significant in at least one cell line (FDR < 0.01). Color represents enrichment score, while size inversely correlates with significance value.

Article Snippet: Rabbit anti-MTAP Polyclonal Antibody , Cell Signaling Technology , Cat#4158; RRID: AB_1904054.

Techniques: Control, Expressing

Journal: Journal of clinical pathology

Article Title: Clinicopathological characterisation of MTAP alterations in gastrointestinal cancers.

doi: 10.1136/jcp-2023-209341

Figure Lengend Snippet: Figure 1 Therapeutic vulnerability of MTAP null cells by MAT2A and PRMT5 inhibitors MTAP loss results in intracellular accumulation of MTA, which competes with the activating cofactor SAM, causing a decrease in PRMT5 activity. PRMT5 is a key enzyme for the methylation of proproliferative kinases, thus the reduction in PRMT5 activity leads to activation of oncogenic pathways. Targeting MAT2A or PRMT5 in MTAP null tumours is a potential therapeutic strategy. Created with BioRender.com. Me, methyl group; MTA, methylthioadenosine; MTR-1P, 5-methylthioribose- 1-phosphate; MTAP, methylthioadenosine phosphorylase; PRMT5, protein arginine methyltransferase 5; SAH, S-adenosyl homocysteine; SAM, methyl donor S-adenosyl-L-methionine; WDR77, WD repeat domain 77; wt, wild type.

Article Snippet: We further assessed MTAP protein expression by immunohistochemistry (IHC) using a Rabbit polyclonal anti- MTAP antibody (1:200 dilution, ProteinTech, Tucson, Arizona, USA) in selected tumours harbouring MTAP alterations, other than MTAP loss, to evaluate whether these were associated with loss of protein expression, thus potentially conferring sensitivity to targeted agents currently under clinical investigation in dedicated clinical trials.

Techniques: Activity Assay, Methylation, Activation Assay

Journal: Journal of clinical pathology

Article Title: Clinicopathological characterisation of MTAP alterations in gastrointestinal cancers.

doi: 10.1136/jcp-2023-209341

Figure Lengend Snippet: Figure 2 No difference in survival analysis of pancreatic cancer patients according to MTAP status in the TCGA PanCancer Atlas cohort (A, B) and the Niguarda Cancer Center cohort (C, D). MTAP, methylthioadenosine phosphorylase; TCGA, The Cancer Genome Atlas.

Article Snippet: We further assessed MTAP protein expression by immunohistochemistry (IHC) using a Rabbit polyclonal anti- MTAP antibody (1:200 dilution, ProteinTech, Tucson, Arizona, USA) in selected tumours harbouring MTAP alterations, other than MTAP loss, to evaluate whether these were associated with loss of protein expression, thus potentially conferring sensitivity to targeted agents currently under clinical investigation in dedicated clinical trials.

Techniques:

Journal: Journal of clinical pathology

Article Title: Clinicopathological characterisation of MTAP alterations in gastrointestinal cancers.

doi: 10.1136/jcp-2023-209341

Figure Lengend Snippet: Figure 3 Immunohistochemistry (IHC) staining of two cases of metastatic colorectal cancer harbouring MTAP alterations other than gene loss. (A, B) Samples were collected from a patient in which an MTAP-CDKN2B truncation was identified by next-generation sequencing (NGS), in which both MTAP and p16 IHC revealed a complete lack of expression for both proteins, respectively. (C, D) Samples were collected from a patient in which MTAP M140V point mutation was identified by NGS, in which both MTAP and p16 protein expression was maintained, respectively. MTAP IHC staining was performed using a rabbit polyclonal anti-MTAP antibody (1:200 dilution, Pro-teinTech, Tucson, AZ). As a control, we also evaluated the expression of the protein p16 (the product of CDKN2A gene) using the p16, Clone:JC2, mouse monoclonal antibody (1:100 dilution, Gennova, Sevillia). Only samples with complete MTAP and/or p16 protein loss were considered MTAP deficient (IHC score 0).

Article Snippet: We further assessed MTAP protein expression by immunohistochemistry (IHC) using a Rabbit polyclonal anti- MTAP antibody (1:200 dilution, ProteinTech, Tucson, Arizona, USA) in selected tumours harbouring MTAP alterations, other than MTAP loss, to evaluate whether these were associated with loss of protein expression, thus potentially conferring sensitivity to targeted agents currently under clinical investigation in dedicated clinical trials.

Techniques: Immunohistochemistry, Next-Generation Sequencing, Expressing, Mutagenesis, Control

Journal: Scientific Reports

Article Title: MTAP-deficiency could predict better treatment response in advanced lung adenocarcinoma patients initially treated with pemetrexed-platinum chemotherapy and bevacizumab

doi: 10.1038/s41598-020-57812-2

Figure Lengend Snippet: Clinical pathological features of 165 patients with advanced-stage non-small cell lung cancer.

Article Snippet: The primary polyclonal rabbit anti-human MTAP antibody (1:500; Thermo Fisher Scientific, US) and secondary antibody were applied to stain the slides.

Techniques: Expressing, Mutagenesis

Journal: Scientific Reports

Article Title: MTAP-deficiency could predict better treatment response in advanced lung adenocarcinoma patients initially treated with pemetrexed-platinum chemotherapy and bevacizumab

doi: 10.1038/s41598-020-57812-2

Figure Lengend Snippet: Clinical response of first-line therapy for 165 patients and associations with MTAP expression.

Article Snippet: The primary polyclonal rabbit anti-human MTAP antibody (1:500; Thermo Fisher Scientific, US) and secondary antibody were applied to stain the slides.

Techniques: Expressing

Journal: Scientific Reports

Article Title: MTAP-deficiency could predict better treatment response in advanced lung adenocarcinoma patients initially treated with pemetrexed-platinum chemotherapy and bevacizumab

doi: 10.1038/s41598-020-57812-2

Figure Lengend Snippet: Progression-free survival curve of patients stratified by MTAP expression. The median PFS in the MTAP-low group was 8.1 months, compared to 13.1 months in the MTAP-high group ( p = 0.002).

Article Snippet: The primary polyclonal rabbit anti-human MTAP antibody (1:500; Thermo Fisher Scientific, US) and secondary antibody were applied to stain the slides.

Techniques: Expressing

Journal: Scientific Reports

Article Title: MTAP-deficiency could predict better treatment response in advanced lung adenocarcinoma patients initially treated with pemetrexed-platinum chemotherapy and bevacizumab

doi: 10.1038/s41598-020-57812-2

Figure Lengend Snippet: Overall survival curve of patients stratified by MTAP expression. The median OS was 22 months in the MTAP-low group, whereas it was 32 months in the MTAP-high group ( p = 0.044). The 1- and 2-year survival were higher in the MTAP-high group (88.8% vs. 79.5%; 67.8% vs. 40.7%, respectively).

Article Snippet: The primary polyclonal rabbit anti-human MTAP antibody (1:500; Thermo Fisher Scientific, US) and secondary antibody were applied to stain the slides.

Techniques: Expressing

Journal: Scientific Reports

Article Title: MTAP-deficiency could predict better treatment response in advanced lung adenocarcinoma patients initially treated with pemetrexed-platinum chemotherapy and bevacizumab

doi: 10.1038/s41598-020-57812-2

Figure Lengend Snippet: Univariate and Multivariable analyses of overall survival.

Article Snippet: The primary polyclonal rabbit anti-human MTAP antibody (1:500; Thermo Fisher Scientific, US) and secondary antibody were applied to stain the slides.

Techniques: Mutagenesis, Expressing